Erkang Pharmaceutical’s Vitamin B6 Injection Passed Consistency Evaluation
June 11, 2025
Source: drugdu
55
On June 9, Erkang Pharmaceutical(300267) released an announcement, vitaminThe B6 injection 1ml:100mg specification has passed the generic drug quality and efficacy consistency evaluation.
The company recently received the "Notice of Approval of Supplementary Drug Application" approved by the State Drug Administration, with the approval number of National Medicine Standard H20258096. The drug is mainly used for the prevention and treatment of vitamin B6 deficiency and is included in the "National Basic Medical Insurance", Work-related Injury Insurance and Maternity Insurance Drug List (2024)”, which is a Class A medical insurance drug.
In the first quarter of 2025, Erkang Pharmaceutical achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 28.11 million yuan.
https://finance.eastmoney.com/a/202506093425512121.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Lenacapavir “zero time difference” landing in Lecheng, China’s HIV prevention and control enters a new era of long-term prevention July 30, 2025
- Reaches innovative drug overseas authorization agreement with GlaxoSmithKline, with potential revenue exceeding $12 billion July 30, 2025
- Biopharma subsidiary obtains clinical approval for feline infectious peritonitis mRNA vaccine July 30, 2025
- Ambroxol hydrochloride drops converted to over-the-counter drugs July 30, 2025
- A new autoimmune drug in China has successfully completed Phase III, outperforming Cosentyx head-to-hea. July 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
